ES2533065T3 - Bencenosulfonamidas útiles como inhibidores de los canales de sodio - Google Patents

Bencenosulfonamidas útiles como inhibidores de los canales de sodio Download PDF

Info

Publication number
ES2533065T3
ES2533065T3 ES11746620.1T ES11746620T ES2533065T3 ES 2533065 T3 ES2533065 T3 ES 2533065T3 ES 11746620 T ES11746620 T ES 11746620T ES 2533065 T3 ES2533065 T3 ES 2533065T3
Authority
ES
Spain
Prior art keywords
los
con
por
para
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11746620.1T
Other languages
English (en)
Spanish (es)
Inventor
Alan Daniel Brown
Marcel John De Groot
Brian Edward Marron
David James Rawson
Thomas Ryckmans
Robert Ian Storer
Paul Anthony Stupple
Nigel Alan Swain
Christopher William West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Icagen Inc
Original Assignee
Pfizer Ltd Great Britain
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain, Icagen Inc filed Critical Pfizer Ltd Great Britain
Application granted granted Critical
Publication of ES2533065T3 publication Critical patent/ES2533065T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES11746620.1T 2010-07-09 2011-07-05 Bencenosulfonamidas útiles como inhibidores de los canales de sodio Active ES2533065T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36292710P 2010-07-09 2010-07-09
US362927P 2010-07-09
US201161492525P 2011-06-02 2011-06-02
US201161492525P 2011-06-02
PCT/IB2011/052974 WO2012004743A1 (en) 2010-07-09 2011-07-05 Benzenesulfonamides useful as sodium channel inhibitors

Publications (1)

Publication Number Publication Date
ES2533065T3 true ES2533065T3 (es) 2015-04-07

Family

ID=45439019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11746620.1T Active ES2533065T3 (es) 2010-07-09 2011-07-05 Bencenosulfonamidas útiles como inhibidores de los canales de sodio

Country Status (8)

Country Link
US (1) US8772293B2 (enExample)
EP (1) EP2590951B1 (enExample)
JP (1) JP5830534B2 (enExample)
AR (1) AR082201A1 (enExample)
CA (1) CA2804593C (enExample)
ES (1) ES2533065T3 (enExample)
UY (1) UY33491A (enExample)
WO (1) WO2012004743A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
WO2012007861A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
EP2593428B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
MX2014005297A (es) * 2011-10-31 2014-09-11 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
WO2013064984A1 (en) * 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
JPWO2013137371A1 (ja) * 2012-03-15 2015-08-03 興和株式会社 新規ピリミジン化合物及びそれらを含有する医薬
WO2013161928A1 (ja) * 2012-04-26 2013-10-31 塩野義製薬株式会社 オキサゾロトリアゾール誘導体およびそれらを含有する医薬組成物
HK1209100A1 (en) 2012-05-22 2016-03-24 基因泰克有限公司 N-substituted benzamides and their use in the treatment of pain
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
KR102038607B1 (ko) * 2012-10-15 2019-10-30 주식회사 대웅제약 소디움 채널 차단제, 이의 제조방법 및 이의 용도
KR20150074123A (ko) 2012-10-26 2015-07-01 머크 샤프 앤드 돔 코포레이션 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 n-치환된 인다졸 술폰아미드 화합물
MX2015011436A (es) 2013-03-14 2016-06-06 Genentech Inc Triazolopiridinas sustituidas y metodos para usarlas.
EP2968234B1 (en) * 2013-03-15 2018-06-27 Chromocell Corporation Sodium channel modulators for the treatment of pain
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
TW201443025A (zh) * 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
JP6445565B2 (ja) 2013-09-10 2018-12-26 クロモセル コーポレイション とう痛及び糖尿病の治療用ナトリウムチャネル調節物質
EP3450428A1 (en) 2013-11-27 2019-03-06 Genentech, Inc. Substituted benzamides and methods of use thereof
US10468036B2 (en) * 2014-04-30 2019-11-05 Accusonus, Inc. Methods and systems for processing and mixing signals using signal decomposition
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
HK1252567A1 (zh) 2015-05-22 2019-05-31 基因泰克公司 被取代的苯甲酰胺和其使用方法
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
AU2016330503B2 (en) 2015-09-28 2021-04-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3372583A4 (en) 2015-11-06 2019-06-05 Daiichi Sankyo Company, Limited METHOD FOR REMOVING A DIMETHOXYBENZYL GROUP
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
WO2017106226A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
JP6938545B2 (ja) 2016-05-20 2021-09-22 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
BR112019007763A2 (pt) 2016-10-17 2019-07-02 Genentech Inc composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
KR20190086772A (ko) 2016-12-09 2019-07-23 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
JP2021514980A (ja) 2018-02-26 2021-06-17 ジェネンテック， インコーポレイテッド 疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
UA127024C2 (uk) 2018-06-13 2023-03-15 Ксенон Фармасьютікалз Інк. Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів
CA3104913A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
EP3844150A1 (en) 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
EP3891157A4 (en) 2018-12-05 2022-08-31 Merck Sharp & Dohme Corp. 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS
TW202216671A (zh) * 2020-06-25 2022-05-01 瑞士商諾華公司 １，４—二取代的嗒𠯤化合物之製造方法
IL313762A (en) * 2021-12-23 2024-08-01 Veralox Therapeutics Preparations and methods of use for the treatment of diseases mediated by 12-lipoxygenase (12-lox)
WO2025160284A1 (en) * 2024-01-23 2025-07-31 The Board Of Trustees Of The University Of Illinois Algorithm for computer-assisted molecular modularization

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR71915B (enExample) 1979-11-27 1983-08-16 Pfizer
EP0194599A3 (en) 1985-03-14 1988-01-20 Nissan Chemical Industries Ltd. Benzamide derivatives, process for producing the same, and soil fungicides containing the same
HUT48799A (en) 1986-08-20 1989-07-28 Fmc Corp Herbicides containing as active substance derivatives of triazolinon and process for production of the active substances
US5084085A (en) 1986-08-20 1992-01-28 Fmc Corporation Herbicidal aryloxyphenyltriazolinones and related compounds
US4845264A (en) 1987-03-05 1989-07-04 Teijin Limited Phenoxycarboxylic acid and herbicide comprising it as active ingredient
US4920132A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920133A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
DE68909958D1 (de) 1988-01-19 1993-11-25 Tanabe Seiyaku Co Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung.
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
HUT54991A (en) 1989-08-11 1991-04-29 Ici Plc Process for producing quinoline derivatives and pharmaceutical compositions comprising such compounds
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
GB2266527A (en) 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
JPH05289262A (ja) 1992-04-10 1993-11-05 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH05307242A (ja) 1992-04-28 1993-11-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JP3101848B2 (ja) 1992-05-15 2000-10-23 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
FR2694295B1 (fr) 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
WO1994013636A1 (en) 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
PT617001E (pt) 1993-03-19 2000-06-30 Merck & Co Inc Derivados do acido fenoxifenilacetico
JPH06347968A (ja) 1993-04-14 1994-12-22 Fuji Photo Film Co Ltd ハロゲン化銀感光材料
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
JP3503839B2 (ja) 1994-05-25 2004-03-08 富士写真フイルム株式会社 ポジ型感光性組成物
CA2195758A1 (en) 1994-08-08 1996-02-22 Scott W. Bagley Phenoxyphenylacetic acid derivatives
WO1996009818A1 (en) 1994-09-27 1996-04-04 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
GB9514031D0 (en) 1995-07-10 1995-09-06 Zeneca Ltd Chemical process
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JP3519218B2 (ja) 1996-08-14 2004-04-12 富士写真フイルム株式会社 ハロゲン化銀写真感光材料および画像形成方法
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
RU2199532C2 (ru) 1997-06-27 2003-02-27 Фудзисава Фармасьютикал Ко., Лтд. Сульфонамидное соединение
US6555584B1 (en) 2000-06-29 2003-04-29 Ajinomoto Co., Inc. Acylsulfonamide derivative
DE19742951A1 (de) 1997-09-29 1999-04-15 Hoechst Schering Agrevo Gmbh Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung
EP1030665A4 (en) 1997-10-17 2002-11-27 Aventis Pharm Prod Inc THERAPEUTIC USE OF CHINOLINE DERIVATIVES
NZ502963A (en) 1997-12-23 2002-06-28 Warner Lambert Co Thiourea and benzamide compounds and methods of treating or preventing inflammatory diseases and atherosclerosis
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GT199900044A (es) 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
KR100693771B1 (ko) 1999-04-28 2007-03-12 사노피-아벤티스 도이칠란트 게엠베하 Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
ATE271868T1 (de) 1999-05-05 2004-08-15 Merck & Co Inc Neue cathechole als antimikrobielle mittel
AU5283900A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2000071510A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
CA2374820A1 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibitors of factor xa
JP2001075213A (ja) 1999-09-07 2001-03-23 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤、その製造方法及びこれを用いたハロゲン化銀写真感光材料
EP1220832A1 (en) 1999-09-29 2002-07-10 Novo Nordisk A/S Novel aromatic compounds
HRP20020324A2 (en) 1999-10-13 2003-08-31 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
KR20020081424A (ko) 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Ｐｐａｒ 매개인자의 치료학적 용도
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
EP1260221A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination treatment for depression and anxiety
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
CA2467261C (en) 2001-11-16 2010-10-12 Toyama Chemical Co., Ltd. Novel benzophenone derivatives or salts thereof
AU2003262805A1 (en) 2002-08-26 2004-03-11 Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors
AU2003273762A1 (en) 2002-10-28 2004-05-13 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
EP1601348A4 (en) 2003-02-28 2008-12-10 Oxigene Inc Compositions and methods with improved therapeutic activity
AR045238A1 (es) 2003-08-08 2005-10-19 Vertex Pharma Compuestos utiles como inhibidores de canales ionicos regulados por voltaje
EP1730118A1 (en) 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
CA2564355C (en) 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
EP1773792A1 (en) 2004-07-30 2007-04-18 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
SI1802579T1 (sl) 2004-10-20 2014-03-31 Merck Serono Sa Derivati 3-arilaminopiridina
JP2008189549A (ja) 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
WO2007068894A2 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
JP2009057282A (ja) 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
EP2010529A1 (en) 2006-04-10 2009-01-07 PainCeptor Pharma Corp. Compositions and methods for modulating gated ion channels
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
RS20090154A (sr) 2006-10-18 2010-10-31 Pfizer Products Inc. Jedinjenja biaril etra uree
NZ579355A (en) 2007-02-01 2012-03-30 Resverlogix Corp 2-(Aryl)-4-oxo-quinazoline derivatives
DE602008000809D1 (de) 2007-03-23 2010-04-29 Icagen Inc Ionenkanal-Hemmer
BRPI0810202A2 (pt) 2007-05-03 2014-10-21 Pfizer Ltd Derivados de piridina
EP2154130A4 (en) 2007-06-07 2011-09-07 Astellas Pharma Inc pyridone
EP2173743A2 (en) * 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
NZ584474A (en) 2007-10-11 2012-06-29 Vertex Pharma Amides useful as inhibitors of voltage-gated sodium channels
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
TW200930368A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
US20090291921A1 (en) 2007-11-20 2009-11-26 Gilead Sciences, Inc. Integrase inhibitors
KR20100098653A (ko) 2007-11-21 2010-09-08 디코드 제네틱스 이에이치에프 염증의 치료를 위한 바이아릴 ｐｄｅ４ 억제제
GB0725214D0 (en) 2007-12-24 2008-02-06 Karobio Ab Pharmaceutical compounds
US20110015065A1 (en) 2008-02-15 2011-01-20 Basf Se Substituted Sulfonic Acid Amide Compounds
EP2119690A1 (en) 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
EP2300471A1 (en) 2008-05-28 2011-03-30 Basf Se Substituted pyridin-4-yl-methyl sulfonamidesas fungicides
KR20110027648A (ko) 2008-06-23 2011-03-16 아스테라스 세이야쿠 가부시키가이샤 술폰아미드 화합물 또는 이의 염
US8107894B2 (en) 2008-08-12 2012-01-31 Raytheon Company Modular solid-state millimeter wave (MMW) RF power source
CN102348697B (zh) 2009-01-12 2014-12-10 辉瑞股份有限公司 磺酰胺衍生物
JP5289262B2 (ja) 2009-09-30 2013-09-11 京セラドキュメントソリューションズ株式会社 シート搬送装置とこれを備えた画像読取装置及び画像形成装置
EP2590972B1 (en) * 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2526675T3 (es) * 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
EP2593428B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
WO2012007861A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje

Also Published As

Publication number Publication date
US20120010182A1 (en) 2012-01-12
UY33491A (es) 2012-02-29
CA2804593A1 (en) 2012-01-12
JP2013531031A (ja) 2013-08-01
WO2012004743A1 (en) 2012-01-12
EP2590951A1 (en) 2013-05-15
US8772293B2 (en) 2014-07-08
EP2590951B1 (en) 2015-01-07
JP5830534B2 (ja) 2015-12-09
AR082201A1 (es) 2012-11-21
CA2804593C (en) 2015-11-24

Similar Documents

Publication Publication Date Title
ES2533065T3 (es) Bencenosulfonamidas útiles como inhibidores de los canales de sodio
ES2526675T3 (es) N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
ES2532356T3 (es) N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
ES2526541T3 (es) N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
ES2526981T3 (es) N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
EP2593428B1 (en) N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP5053459B2 (ja) スルホンアミド誘導体
ES2532357T3 (es) Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
US20150291514A1 (en) N-Aminosulfonyl Benzamides
ES2526982T3 (es) N-Sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje